Associate Professor, Medicine, University of Maryland School of Medicine
Rheumatology
Dr. Violeta Rus, MD
|
|
Give Review
Violeta practices Rheumatology. She received awards:"CMS Meaningful Use Stage 1 Certification", "Fellow (FACR)" and "Fellow". Violeta Rus, MD is a published doctor. She has 31 publications published. The most current publication "CTL-Promoting Effects of IL-21 Counteract Murine Lupus in the ParentF1 Graft-versus-Host Disease Model." Violeta accepts Medicare payments and is listed with Medicare.gov.
Publications
- CTL-Promoting Effects of IL-21 Counteract Murine Lupus in the Parent→F1 Graft-versus-Host Disease Model.
- RGC-32 is a novel regulator of the T-lymphocyte cell cycle.
- Role of SIRT1 in autoimmune demyelination and neurodegeneration.
- SIRT1 is decreased during relapses in patients with multiple sclerosis.
- Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer.
- Dual role of Response gene to complement-32 in multiple sclerosis.
- IL-21 Promotes Lupus-like Disease in Chronic Graft-versus-Host Disease through Both CD4 T Cell- and B Cell-Intrinsic Mechanisms.
- National character does not reflect mean personality trait levels in 49 cultures.
- Membrane attack by complement: the assembly and biology of terminal complement complexes.
- C5b-9-activated, K(v)1.3 channels mediate oligodendrocyte cell cycle activation and dedifferentiation.
- Exploratory study on oxygen consumption on-kinetics during treadmill walking in women with systemic Lupus erythematosus.
- Epigenetic modifications induced by RGC-32 in colon cancer.
- Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survival.
- TRAIL, DR4 and DR5 are upregulated in kidneys from patients with Lupus nephritis and exert proliferative and proinflammatory effects.
- Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial cells.
- Differential expression and molecular associations of Syk in systemic Lupus erythematosus T cells.
- Complement C5 regulates the expression of insulin-like growth factor binding proteins in Chronic experimental allergic encephalomyelitis.
- Role of response gene to complement 32 in Diseases.
- T cell TRAIL promotes murine Lupus by sustaining effector CD4 Th cell numbers and by inhibiting CD8 CTL activity.
- C5b-9-induced endothelial cell proliferation and migration are dependent on Akt inactivation of forkhead transcription factor FOXO1.
- C5b-9 terminal complex protects oligodendrocytes from apoptotic cell death by inhibiting caspase-8 processing and up-regulating FLIP.
- Increased caspase-3 expression and activity contribute to reduced CD3zeta expression in systemic Lupus erythematosus T cells.
- Increased expression and release of functional tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by T cells from lupus patients with active Disease.
- Gene expression profiling in peripheral blood mononuclear cells from lupus patients with active and inactive Disease.
- Effects of complement C5 on apoptosis in experimental autoimmune encephalomyelitis.
- Effects of membrane attack complex of complement on apoptosis in experimental autoimmune encephalomyelitis.
- Pathogenic T cells in murine Lupus exhibit spontaneous signaling activity through phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways.
- Evidence for aerobic insufficiency in women with systemic Lupus erythematosus.
- Expression of cytokine- and chemokine-related genes in peripheral blood mononuclear cells from Lupus patients by cDNA array.
- RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase.
Schools
Universitatea De Medicina Si Farmacie Iuliu Hatieganu Facultatea De Medicina
St Agnes Hospital
University MD Med School
Procedures Preformed
- Joint Drainage
- Myofascial Trigger Point Injection
- Steroid Injection
Conditions Treated
- Achilles Tendinitis
- Ankylosing Spondylitis
- Antiphospholipid Syndrome (APS)
- Arthritis
- View All
Doctors Specialties
- Rheumatology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Fellow (FACR)
- Fellow
Education
-
University of Maryland -
Iuliu Hatieganu University of Medicine and Pharmacy
Hospital
-
University of Maryland Medical Center
Drug Facts
| NPI NUMBER | 1285681320 | |
| NPPES Provider LastName | RUS | |
| NPPES Provider FirstName | VIOLETA | |
| NPPES Provider ZIPCode | 212011544 | |
| NPPES Provider State | MD | |
| Specialty Description | Rheumatology | |
| Total Claim Count | 150.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 15.0 | |
| Percent Opioid Claims | 10.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1285681320 |
| Last Name Of The Provider | RUS |
| First Name Of The Provider | VIOLETA |
| View All |
Similar Doctors
|
|
Dr. Howard W. Hauptman, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David Hellmann, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Laura Hummers, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. John V. Conte Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Grant H. Louie, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sangeeta Sule, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kent K. Huston, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Fredrick Wigley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Zaki Abou Zahr, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amit Golding, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Olga V. Szalasny, MD
This Doctor is OpenDoctor Recommended.
|